The third edition of this work represents a major enhancement to the second edition published in 1975. Both analytical interference and physiologic changes are documented for drug assays as well as clinical chemistry. There are 3969 references cited.
The book is divided into five major sections (plus an introduction). The first two sections are the Laboratory Test Index and the Drug Index, which are compilations of search terms. Both American and European drug names seem to be well represented, The next two sections present the business end of the reference: Drug Laboratory Test Listings compiles for each test a list of drugs that alter results, and Drug Listings compiles for each drug a list of the tests known to be affected or not affected by it. For example, digoxin is found in the Laboratory Test Listings section as a drug assay with a list of drugs known to affect digoxin measurements; it is also found in the Drug Listings section as a drug with a list of laboratory tests or assays with which it interferes. The last section is the list of literature references (all with complete citations), most of which appear to be primary literature reports.
The monographs in both parts are divided by physiologic matrix and according to whether there is no change, an increase, or a decrease in the test result. Further subdivisions categorize the interference as either analytical or physiologic; this reference therefore serves as both a listing of assay interferences and physiologic or pharmacokinetic drug-drug and drug-test interactions. Each listed statement is referenced.
This work should find wide use in institutions where drug-laboratory interference is considered to be a source of clinical problems. The inclusion of references reporting no interaction removes doubt in many cases as to whether there is no problem or whether the potential problem has not been studied. Many of the monographs discuss interference or lack or it with specifically named assay methods or instruments, a feature that allows an inquiry to be institution-specific. In most instances, where assay interference is reported, concentrations of the interfering agent are specified, allowing the user to decide whether the interference is significant in real-life clinical situations. ClinicalPharmacist /ll PresbyterianIntercommunity Hospital 12401 WashingtonBoulevard Whittier.California 90602
As an information source for drug-drug interactions, the reference is inferior to other drug-drug interactions references because clinical significance is not discussed and because the number of references for most interactions does not compare with those of works whose focus is this type of interaction. Even so, the drug-drug interactions of major importance seem to be well described.
Although the introduction is dated June 1990, the latest references appear to be from 1987. Given the delays in publishing books, this may be about as well as could have been done. This does not mean that drugs released since 1987 are not represented, because many of the citations are of works published during the investigational stage of the drugs discussed.
I would recommend this book to institutional practitioners in any setting in which the pharmacist has access to laboratory data or is involved in making drug therapy recommendations. Despite its high price, individuals providing consultant service outside institutions might also find it a worthwhile investment. Consideration of drug therapy as a contributor to observed patient problems is the special province of the clinical pharmacist, and aberrant laboratory results certainly should not be overlooked by pharmacists involved in patient care. Drug Safety in Pregnancy, authored by two physicians specializing in pharmacology at the University of Cape Town (South Africa) and the University of Groningen (The Netherlands), respectively, is a unique book in the field of teratology. It is unique in the manner in which the authors have presented their review of the literature and in the price that the publisher has set for it. Drug Safety in Pregnancy is a part of the Elsevier series on drug toxicity and is linked with Meyler's Side Effects of Drugs and the Side Effects ofDrugs Annuals.
The book is organized around 35 chapters, 13 appendixes, and 2 indexes. The chapters cover either individual drugs (thalidomide, lithium, ethanol, caffeine, penicillamine, and gold) or classes of drugs (e.g., amphetamines, drugs of abuse, neuroleptics, anticonvulsants). Each chapter starts with a brief introductory discussion of the drug(s) designed to give the reader a flavor of the information to follow. Animal data, if deemed pertinent to understanding the mechanisms of fetal toxicity or to the use of the agent in clinical practice, are presented and followed by human studies. The latter are categorized by the toxic effects observed. For ex-Dlep, The Annals ofPharmacotherapy • 1991 September, Volume 25 • 1017
